Xcout Intel
Accent Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Accent Therapeutics among biotechnology companies — ranked by similarity to what Accent Therapeutics actually does, not by market-cap band.
Subscribe to see Accent Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Accent Therapeutics
Accent Therapeutics, Inc. is a biopharmaceutical company headquartered in Lexington, Massachusetts, focused on translating scientific research into novel therapeutics. The company conducts clinical trials, such as Phase 1/2 studies, targeting oncology and other serious diseases.
Accent Therapeutics at a glance
Accent Therapeutics is a biotechnology company headquartered in United States. It has raised at least $75M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Series C, raised $75M in January 2024. Xcout tracks 15 named people at Accent Therapeutics, including Shakti Narayan (Chief Executive Officer).
Accent Therapeutics leadership
- Shakti NarayanChief Executive Officer
- David BrowerChief Business Officer & Head of Finance
- Jason SagerChief Medical Officer
- Serena SilverChief Scientific Officer
- Srinivas ParthasarathyVice President, Business Development & Strategy and Chief of Staff
- Kevin McGannVice President, Finance
9 more named people on record for Accent Therapeutics, with roles, board committees and tenure — see the full roster →
Accent Therapeutics funding rounds
At least $75M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $75M | 14 named | |
| — | Undisclosed | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Accent Therapeutics competitors
Ranked by semantic similarity — how close each company is to Accent Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts. The company is engaged in the research and development of drug candidates for the treatment of human cancers.
Similar biotechnology company
Auron Therapeutics, Inc. is a biotechnology company headquartered in Newton, Massachusetts. The company focuses on targeting cell states to deliver next-generation targeted cancer therapies.
Similar biotechnology company
Agenus Inc. is a biotechnology company headquartered in Lexington, Massachusetts, focused on the discovery and development of better immunotherapies and cancer treatments.
Similar biotechnology company
Triana Biomedicines, Inc. is a private biotechnology company focused on targeted molecular glue discovery. The company is headquartered in Lexington, Massachusetts.
Similar biotechnology company
Centessa Pharmaceuticals LLC is a biotechnology research company headquartered in Boston, Massachusetts, United States. The company comprises leaders, innovators, and scientists dedicated to pursuing and developing transformational medicines for patients.
Similar biotechnology company
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Similar biotechnology company
PIC Therapeutics, Inc. is a biopharmaceutical company headquartered in Natick, Massachusetts, dedicated to developing life-changing medicines for patients with cancer. The company focuses on oncology research and therapeutic product development.
Biotech
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Biotech
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Similar biotechnology company
Kinaset Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing novel therapeutics.
Similar biotechnology company
Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company with principal executive offices located in Cambridge, Massachusetts. The company went public through a reverse merger and is involved in therapeutic acquisitions and development.
Biotech
Foghorn Therapeutics is a biopharmaceutical company headquartered in Watertown, Massachusetts. The company is pioneering a new class of medicines that treat serious diseases by leveraging insights into the chromatin regulatory system.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Accent Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Accent Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →